Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.

A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.

Nakagawa Y, Yanagita RC, Hamada N, Murakami A, Takahashi H, Saito N, Nagai H, Irie K.

J Am Chem Soc. 2009 Jun 10;131(22):7573-9. doi: 10.1021/ja808447r.

PMID:
19449873
2.

Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ.

Irie K, Yanagita RC, Nakagawa Y.

Med Res Rev. 2012 May;32(3):518-35. doi: 10.1002/med.20220. Review.

PMID:
22539107
3.

Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.

Irie K, Yanagita RC.

Chem Rec. 2014 Apr;14(2):251-67. doi: 10.1002/tcr.201300036. Review.

PMID:
24677503
4.

Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.

Yanagita RC, Kamachi H, Tanaka K, Murakami A, Nakagawa Y, Tokuda H, Nagai H, Irie K.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6064-6. doi: 10.1016/j.bmcl.2010.08.051.

PMID:
20817520
5.
6.
7.

The effect of bryostatin on protein kinase C-regulated functions in human T lymphocytes and epidermal keratinocytes.

Galron D, Tamir A, Gelkop S, Grossman N, Isakov N.

Immunol Lett. 1993 Dec;39(1):17-22.

PMID:
8144186
8.

The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.

Wender PA, Hinkle KW, Koehler MF, Lippa B.

Med Res Rev. 1999 Sep;19(5):388-407. Review.

PMID:
10502742
9.

Differential roles of the tandem C1 domains of protein kinase C delta in the biphasic down-regulation induced by bryostatin 1.

Lorenzo PS, Bögi K, Hughes KM, Beheshti M, Bhattacharyya D, Garfield SH, Pettit GR, Blumberg PM.

Cancer Res. 1999 Dec 15;59(24):6137-44.

10.

Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin.

Lee HW, Smith L, Pettit GR, Bingham Smith J.

Am J Physiol. 1996 Jul;271(1 Pt 1):C304-11.

PMID:
8760059
11.

The practical synthesis of a novel and highly potent analogue of bryostatin.

Wender PA, Baryza JL, Bennett CE, Bi FC, Brenner SE, Clarke MO, Horan JC, Kan C, Lacôte E, Lippa B, Nell PG, Turner TM.

J Am Chem Soc. 2002 Nov 20;124(46):13648-9.

PMID:
12431074
13.

Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh.

al-Katib A, Mohammad RM, Khan K, Dan ME, Pettit GR, Sensenbrenner LL.

J Immunother Emphasis Tumor Immunol. 1993 Jul;14(1):33-42.

PMID:
8399068
14.

Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.

Kikumori M, Yanagita RC, Tokuda H, Suzuki N, Nagai H, Suenaga K, Irie K.

J Med Chem. 2012 Jun 14;55(11):5614-26. doi: 10.1021/jm300566h.

PMID:
22625994
15.
16.

Synthesis and biological activities of the amide derivative of aplog-1, a simplified analog of aplysiatoxin with anti-proliferative and cytotoxic activities.

Hanaki Y, Yanagita RC, Sugahara T, Aida M, Tokuda H, Suzuki N, Irie K.

Biosci Biotechnol Biochem. 2015;79(6):888-95. doi: 10.1080/09168451.2014.1002452.

PMID:
25612633
18.

Neuroprotective versus tumorigenic protein kinase C activators.

Nelson TJ, Alkon DL.

Trends Biochem Sci. 2009 Mar;34(3):136-45. doi: 10.1016/j.tibs.2008.11.006. Review.

PMID:
19233655
19.

Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV).

Gulakowski RJ, McMahon JB, Buckheit RW Jr, Gustafson KR, Boyd MR.

Antiviral Res. 1997 Jan;33(2):87-97.

PMID:
9021050
20.
Items per page

Supplemental Content

Support Center